Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors
Oncology·MeSH: Gastrointestinal Stromal Tumors
Prevalence
30.0 / 100K
2 drugs in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
Phase 2(1)
| Drug | Company |
|---|---|
| Bezuclastinib | Cogent Biosciences, Inc. (COGT) |
Compare drugs
Frequently asked questions
How many drugs are in development for Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors?
BioSniper tracks 2 drugs in development for Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors across 1 company.
How many clinical trials target Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors?
There are 1 clinical trial targeting Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors tracked by BioSniper.
What is the prevalence of Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors?
The estimated prevalence of Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors is approximately 30.0 per 100,000 population.
Deep-dive into Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis